Advertisement

Improved Perfusion Through the Aerated Part of the Lung by Prostacyclin Administration

  • D. Pappert
  • M. Max
  • R. Rossaint
Conference paper

Abstract

Severe ventilation-perfusion mismatching and the development of pulmonary hypertension as a consequence of a diffuse and severe inflammation of the lung are characteristic for the acute respiratory failure (ARF) or acute respiratory distress syndrome (ARDS). The raise in pulmonary vascular resistance (PVR) is triggered by the hypoxic pulmonary vasoconstriction (HPV), a compensatory physiologic response to hypoxia. Additionally, the alteration of the vascular bed with an increase of capillary permeability and altered transcapillary filtration pressures promotes the shift of protein rich fluid to the interstitium and thus the development of high permeability pulmonary edema. An up to twofold increase in lung weight results in progressive atelectasis in the dependent parts of the lung due to increased gravitational forces. This, in combination with flooding of the alveolar space with proteinaceous fluid, decreases alveolar ventilation and promotes shunt perfusion and thereby the reduction in arterial oxygenation. The increase in intrapulmonary right to left shunt is mainly responsible for profound hypoxemia, whereas a reduction of diffusion capacity may play only a minor role.

Keywords

Pulmonary Hypertension Acute Respiratory Distress Syndrome Pulmonary Artery Pressure Acute Respiratory Failure Adult Respiratory Distress Syndrome 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Hawkins JW, Dunn MI (1990) Primary pulmonary hypertension in adults. Clin Cardiol 13: 382–387PubMedCrossRefGoogle Scholar
  2. 2.
    Melot C, Lejeune P, Leeman M et al (1989) Prostaglandin E1 in the adult respiratory distress syndrome. Benefit for pulmonary hypertension and cost for pulmonary gas exchange. Am Rev Respir Dis 139:106–110PubMedCrossRefGoogle Scholar
  3. 3.
    Radermacher P, Santak B, Becker H et al (1989) Prostaglandin E1 and nitroglycerin reduce pulmonary capillary pressure but worsen ventilation-perfusion distributions in patients with adult respiratory distress syndrome. Anesthesiology 70:601–606PubMedCrossRefGoogle Scholar
  4. 4.
    Dujic Z, Eterovic D, Tocilj J et al (1993) About mechanisms of prostaglandin E1 induced deterioration of pulmonary gas exchange in COPD patients. Clin Physiol 13:497–506PubMedCrossRefGoogle Scholar
  5. 5.
    Rossaint R, Falke KJ, Lopez FA et al (1993) Inhaled nitric oxide for the adult respiratory distress syndrome. N Engl J Med 328:399–405PubMedCrossRefGoogle Scholar
  6. 6.
    Fratacci MD, Frostell CG, Chen TY et al (1991) Inhaled nitric oxide. A selective pulmonary vasodilator of heparin-protamine vasoconstriction in sheep. Anesthesiology 75:990–999PubMedCrossRefGoogle Scholar
  7. 7.
    Frostell CG, Fratacci M, Wain JC et al (1991) Inhaled nitric oxide. A selective pulmonary vasodilator reversing hypoxic pulmonary vasoconstriction. Circulation 83:2038–2047PubMedCrossRefGoogle Scholar
  8. 8.
    Enson Y (1989) Pulmonary hypertension and its consequences. In: Baum GL, Wolinsky E (eds) Textbook of Pulmonary Diseases, 4th edn. Little, Brown and Company, Boston Toronto, pp 1139–1162Google Scholar
  9. 9.
    Higenbottam T, Cremona G (1993) Acute and chronic hypoxic pulmonary hypertension. Eur Respir J 6:1207–1212PubMedGoogle Scholar
  10. 10.
    Rizk D (1994) Primary pulmonary hypertension. West J Med 161:509–510PubMedGoogle Scholar
  11. 11.
    Higenbottam TW, Spiegelhalter D, Scott JP et al (1993) Prostacyclin (epoprostenol) and heart-lung transplantation as treatments for severe pulmonary hypertension. Br Heart J 70: 366–370PubMedCrossRefGoogle Scholar
  12. 12.
    Walmrath D, Schneider T, Pilch J et al (1993) Aerosolised prostacyclin in adult respiratory distress syndrome. Lancet 342:961–962PubMedCrossRefGoogle Scholar
  13. 13.
    Pappert D, Busch T, Gerlach H et al (1995) Aerosolized prostacyclin versus inhaled nitric oxide in children with severe acute respiratory distress syndrome. Anesthesiology 82: 1507–1511PubMedCrossRefGoogle Scholar
  14. 14.
    Wetzel RC (1995) Aerosolized prostacyclin. In search of the ideal pulmonary vasodilator. Anesthesiology 82:1315–1317PubMedCrossRefGoogle Scholar
  15. 15.
    Walmrath D, Schneider T, Pilch J et al (1995) Effects of aerosolized prostacyclin in severe pneumonia. Impact of fibrosis. Am J Respir Crit Care Med 151:724–730PubMedGoogle Scholar
  16. 16.
    Welte M, Zwissler B, Habazettl H et al (1993) PGI2 Aerosol versus nitric oxide for selective pulmonary vasodilation in hypoxic pulmonary vasoconstriction. Eur Surg Res 25:329–340PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Italia 1997

Authors and Affiliations

  • D. Pappert
  • M. Max
  • R. Rossaint

There are no affiliations available

Personalised recommendations